Tissue-specific antigens for cancer immunotherapy
AssigneeBiontech US Inc.
InventorsMichael Steven Rooney, Lauren Elizabeth Stopfer
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions relating to tissue-specific antigens, and methods for identifying tissue-specific antigens. Also provided herein are pharmaceutical compositions and methods of treatment that relate to tissue-specific antigens.
Claims22
1-94. (canceled)
A method of treating a disease or condition in a human subject in need thereof, comprising:
- administering a composition to the human subject, wherein the composition comprises:
- (a) a tissue-specific antigen peptide comprising an epitope sequence of a protein, wherein the epitope sequence is expressed by a diseased cell of a target tissue of the human subject;
- (b) a polynucleotide encoding the tissue-specific antigen peptide;
- (c) one or more antigen presenting cells (APCs) presenting the epitope sequence;
- (d) a T cell receptor (TCR) specific to a complex of (i) the epitope sequence and (ii) a protein encoded by an HLA allele of the human subject;
- or
- (e) a population of immune cells from a biological sample comprising at least one antigen specific T cell comprising the TCR;
- wherein the epitope sequence binds to or is predicted to bind to a protein encoded by an HLA allele expressed by the human subject, and
- wherein the tissue-specific antigen epitope gene has an expression level in the diseased cell of a target tissue of the human subject that is at least 2 fold more than an expression level of the tissue-specific antigen epitope gene in cells of each non-target tissue of the subject, wherein the tissue-specific antigen is specific to a non-essential tissue, and
- wherein the non-essential tissue is a tissue not required for survival of a human.
A method of preparing T cells comprising a T cell receptor (TCR) specific to a complex of (i) an epitope sequence of a tissue specific antigen peptide and (ii) a protein encoded by an HLA allele of a human subject, the method comprising:
- (a) contacting a T cell ex vivo with an antigen peptide in complex with an HLA of an APC, wherein the T cell has reduced on no tolerance for the antigenic peptide,
- (b) determining a sequence of a TCR of the T cell that recognizes the antigen peptide in complex with the HLA, wherein the T cell has reduced or no immune tolerance to a tissue of origin of the antigen peptide;
- (c) (i) expanding the T cell in presence of the antigen peptide in complex with the HLA, or (ii) expressing a recombinant polynucleic acid encoding the sequence of the TCR in isolated T cells;
- thereby preparing the T cells comprising the TCR;
- and
- wherein the T cell is from a subject, wherein the tissue-specific antigen is specific to a non-essential tissue, and wherein the non-essential tissue is a tissue not required for survival of a human.
A composition comprising:
- (a) a tissue-specific antigen peptide comprising an epitope sequence of a polypeptide encoded by a gene selected from the group consisting of KLK2, KLK3 and KLK4;
- (b) a polynucleotide encoding the tissue-specific antigen peptide;
- (c) one or more antigen presenting cells (APCs) presenting the epitope sequence;
- (d) a T cell receptor (TCR) or an antibody, or a functional part thereof that is specific to a complex of (i) the epitope sequence and (ii) a protein encoded by an HLA allele;
- or
- (e) a population of immune cells from a biological sample comprising at least one antigen specific T cell comprising the TCR.
Dependencies are inferred from the claim text.